Welcome to MabThera.com
MabThera.com is a comprehensive resource for healthcare professionals outside the United States who are interested in MabThera (rituximab) and the treatment of non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukaemia (CLL). This site also provides information on NHL and CLL epidemiology, diagnosis, staging and prognostic factors. Data from pivotal clinical trials of MabThera in NHL and CLL, including new data on the use of MabThera maintenance in first-line follicular lymphoma (FL), are available.
